Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): Trial results and interleukin-6 analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago phase 2 consortium

Cancer

Volumn 115, Issue 23, 2009, Pages 5541-5549

  Bradley, Deborah ^a   Rathkopf, Dana ^b   Dunn, Rodney ^a   Stadler, Walter M ^c   Liu, Glenn ^d   Smith, David C ^a   Pili, Roberto ^e   Zwiebel, James ^f   Scher, Howard ^b   Hussain, Maha ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATININE; HEMOGLOBIN; INTERLEUKIN 6; PROSTATE SPECIFIC ANTIGEN; VORINOSTAT;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; TASTE DISORDER; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT RESPONSE; URINARY FREQUENCY; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 72249110437     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24597     Document Type: Article

References (42)

1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520. (Pubitemid 39315318)
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512. (Pubitemid 39315317)
3. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-5552. (Pubitemid 47255934)
4. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5:981-989. (Pubitemid 350080267)
5. Fantin VR, Richon VM. Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications. Clin Cancer Res. 2007;13:7237-7242.
6. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216. (Pubitemid 30627729)
7. Iacopino F, Urbano R, Graziani G, Muzi A, Navarra P, Sica G. Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. Int J Oncol. 2008;32:1293-1303.
8. Arts J, Angibaud P, Marien A, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97:1344-1353. (Pubitemid 350114783)
9. Kulp SK, Chen CS, Wang DS, Chen CY. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res. 2006;12:5199-5206. (Pubitemid 44453349)
10. Kuefer R, Hofer MD, Altug V, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004;90:535-541. (Pubitemid 38258278)
11. Qian DZ, Kato Y, Shabbeer S, et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006;12:634-642. (Pubitemid 43166159)
12. Lai MT, Yang CC, Lin TY, Tsai FJ, Chen WC. Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urol Oncol. 2008;26:182-189. (Pubitemid 351288559)
13. Hassig CA, Symons KT, Guo X, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008;7:1054-1065.
14. Sargeant AM, Rengel RC, Kulp SK, et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2008;68:3999-4009.
15. Qian DZ, Wei YF, Wang X, Kato Y, Cheng L, Pili R. Antitumor activity of the histone deacetylase inhibitor MS- 275 in prostate cancer models. Prostate. 2007;67:1182-1193. (Pubitemid 47221885)
16. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247-1252. (Pubitemid 350106355)
17. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007; 109:31-39. (Pubitemid 46053039)
18. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109-3115. (Pubitemid 47218059)
19. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003;9(10 pt 1):3578-3588. (Pubitemid 37169221)
20. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol. 2005;2:150-157.
21. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23:3923-3931. (Pubitemid 46218695)
22. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060-1066.
23. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000;60:5165-5170.
24. Marrocco DL, Tilley WD, Bianco-Miotto T, et al. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007;6:51-60. (Pubitemid 46209918)
25. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999; 161:182-187. (Pubitemid 29422316)
26. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 1995;45:542-549.
27. Hoosein N, Abdul M, McCabe R, et al. Clinical significance of elevation in neuroendocrine factors and interleukin- 6 in metastatic prostatic carcinoma. Urol Oncol: Sem and Orig Investig. 1995;1:246-251.
28. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999;41: 127-133. (Pubitemid 29446967)
29. Woods Ignatoski KM, Friedman J, Escara-Wilke J, et al. Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy. J Interferon Cytokine Res. In press.
30. Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res. 2006;12:5578-5586. (Pubitemid 44497276)
31. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin- 6 and prostate cancer progression. Cytokine Growth Factor Rev. 2001;12:33-40.
32. Choi Y, Park SK, Kim HM, et al. Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp Mol Med. 2008;40:574-581. (Pubitemid 352789098)
33. Lin HS, Hu CY, Chan HY, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen- induced arthritis in rodents. Br J Pharmacol. 2007; 150:862-872.
34. Leoni F, Fossati G, Lewis EC, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005;11:1-15.
35. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004;101:540-545.
36. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
37. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467. (Pubitemid 29517916)
38. Beekman KW, Fleming MT, Scher HI, et al. Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer. 2005;4:86-90. (Pubitemid 41474602)
39. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110:1911-1928. (Pubitemid 350036849)
40. Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008;49:502-507. (Pubitemid 351298334)
41. Siegel D, Hussein M, Belani C, et al. Safety and tolerability of vorinostat-Experience from the vorinostat clinical trial program [abstract]. J Clin Oncol. 2008;26. Abstract 14580.
42. Parker C, Molife R, Karavasilis V, et al. Romidepsin (FK228), a histone deacetylase inhibitor: final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC) [abstract]. J Clin Oncol. 2007;25(18 suppl). Abstract 15507.